Can Relapsing-Remitting MS Progress Without Relapses?
At a Glance
Yes. Relapsing-remitting MS can gradually worsen without obvious relapses through progression independent of relapse activity (PIRA). Doctors look for persistent changes over months, rule out temporary triggers, and use physical, hand, and cognitive tests to track progression.
In this answer
5 sections
Yes. Relapsing-remitting multiple sclerosis (RRMS) can gradually worsen even if you are not having noticeable relapses or flare-ups [1]. Neurologists refer to this as Progression Independent of Relapse Activity (PIRA).
Research shows that this gradual progression is common and can begin early in the disease, though estimates of how often it happens vary depending on the study and how progression is defined [2][3]. It is important to know that experiencing PIRA does not automatically mean you have transitioned to secondary progressive MS (SPMS). SPMS is a specific clinical classification made by a neurologist after a long period of sustained change, not based on a single symptom, a bad week, or one test score [4].
Because patients often assume that a lack of attacks means their disease is completely stable, noticing that symptoms are slowly worsening can be confusing and alarming. Understanding how to recognize and track these changes can help you and your care team take proactive steps.
Relapse, Pseudo-Relapse, or Progression?
Not every increase in symptoms means your MS is permanently progressing [5]. It is critical to distinguish between three different situations:
- Relapse: A sudden appearance of new or worsening neurological symptoms that lasts at least 24 hours and occurs without a fever or infection [6]. If you experience this, contact your MS care team. (Note: If you experience sudden, severe, stroke-like symptoms—such as facial drooping, an inability to speak, or sudden severe weakness—seek emergency medical care immediately.)
- Pseudo-Relapse (Symptom Fluctuation): A temporary worsening of symptoms triggered by heat, stress, poor sleep, or an infection (like a urinary tract infection). These symptoms typically improve once the trigger is resolved [7].
- Progression (PIRA): A gradual, subtle worsening of abilities that does not improve and is confirmed over several months (often 6 to 12 months), separate from any relapses [3].
To help your doctor sort this out, consider keeping a brief symptom log. Track what specific activities are harder, how long the issue lasts, and whether you are experiencing triggers like heat or illness.
Recognizing Gradual Worsening
Unlike a relapse, which is usually abrupt, PIRA happens very gradually [2]. You might not notice changes from day to day, but looking back over six to twelve months, you may realize certain tasks require much more effort. This subtle worsening can affect several areas:
- Walking and Balance: Your walking pace may slow down, or you might experience more tripping and near-falls [8].
- Hand Dexterity: Fine motor skills, like buttoning a shirt or handwriting, may become more clumsy [8].
- Cognition: You may experience trouble with memory, multitasking, or processing speed (how fast your brain can take in and use information). Cognitive decline can happen completely independently of physical worsening [9].
- Endurance and Fatigue: You may find your physical or mental stamina decreasing. While fatigue alone does not prove your disease is progressing, it is a significant symptom that should be addressed [7].
How Your Doctor Measures Progression
Neurologists traditionally use the Expanded Disability Status Scale (EDSS), a physical exam scoring system. However, the EDSS is heavily focused on walking. If your doctor relies only on the EDSS, they might miss changes in your hands or memory [10][11].
To accurately track subtle worsening, your care team may use additional quick functional tests:
- Timed 25-Foot Walk (T25FW): A test to precisely measure your walking speed [10].
- 9-Hole Peg Test (9HPT): A timed test of finger dexterity where you place small pegs into holes [10].
- Symbol Digit Modalities Test (SDMT): A 5-minute written or verbal test that screens for changes in cognitive processing speed [11].
If a test shows a worse score, your doctor will not automatically assume the change is permanent. Performance can vary due to sleep, mood, pain, or simply a bad day. They will usually repeat the test 6 to 12 months later to see if the change is confirmed and sustained over time [3][6].
What About My MRI (Magnetic Resonance Imaging)?
It is a common misconception that if your routine brain MRI is “stable” (meaning it shows no new active inflammatory spots or lesions), your MS cannot be progressing. While a stable MRI is reassuring because it means your medication is controlling new inflammation, it does not rule out gradual clinical progression [5].
Researchers believe that PIRA is driven by gradual nerve damage and tissue loss rather than active inflammatory attacks. While advanced imaging used in research can detect these deeper changes—such as brain atrophy (overall brain volume loss)—these specialized scans are not routinely used or needed to make individual treatment decisions in standard clinics [12][13]. Your day-to-day physical and cognitive function remains the best indicator of progression [14].
Taking Action: Treatment and Rehabilitation
Experiencing gradual progression does not mean you have failed treatment, nor does it mean you are helpless.
- Disease-Modifying Therapies (DMTs): DMTs are highly effective at preventing inflammatory relapses and new MRI lesions, which cause their own type of worsening [15]. However, evidence on how well different DMTs prevent non-inflammatory progression (PIRA) is mixed [16][17]. You should not stop or change your medication on your own just because you notice gradual worsening. Treatment decisions should be made with your doctor, weighing inflammation control, side effects, and your personal health goals.
- Targeted Rehabilitation: Physical and occupational therapy do not “cure” MS progression, but they are vital for maximizing your abilities. A physical therapist can tailor an individualized exercise program (incorporating balance, aerobic, or resistance training) to your specific needs and limitations [18][19]. This helps manage symptoms, improve endurance, and reduce fall risk [20].
- Evaluate Other Causes: Worsening symptoms aren’t always caused by MS progression. Your doctor should evaluate and treat other factors like poor sleep, depression, medication side effects, or subtle infections, which can mimic or amplify progression [7].
Common questions in this guide
Can relapsing-remitting MS worsen even when I have no relapses?
What is progression independent of relapse activity in MS?
How can I tell whether worsening MS symptoms are a relapse, pseudo-relapse, or progression?
Can MS progress if my MRI is stable?
What tests do doctors use to detect gradual MS progression?
What should I do if my MS symptoms are slowly getting worse without a relapse?
Related questions
Show more
Get notified when new evidence is published on relapsing-remitting multiple sclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (20)
- 1
Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.
Müller J, Cagol A, Lorscheider J, et al.
JAMA neurology 2023; (80(11)):1232-1245 doi:10.1001/jamaneurol.2023.3331.
PMID: 37782515 - 2
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E, Bellinvia A, Fonderico M, et al.
Brain : a journal of neurology 2022; (145(8)):2796-2805 doi:10.1093/brain/awac111.
PMID: 35325059 - 3
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Müller J, Sharmin S, Lorscheider J, et al.
JAMA neurology 2025; (82(6)):614-625 doi:10.1001/jamaneurol.2025.0495.
PMID: 40227706 - 4
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
Portaccio E, Betti M, De Meo E, et al.
Journal of neurology 2024; (271(8)):5074-5082 doi:10.1007/s00415-024-12448-4.
PMID: 38805052 - 5
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
Strijbis EMM, Mostert J, Comtois J, et al.
Neurology 2025; (104(2)):e210153 doi:10.1212/WNL.0000000000210153.
PMID: 39960455 - 6
Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.
Portaccio E, Betti M, De Meo E, et al.
Neurology 2025; (105(8)):e213977 doi:10.1212/WNL.0000000000213977.
PMID: 40982769 - 7
Assessment of changes in fatigue and cognitive functioning in the absence of progression independent of relapse activity.
Glanz BI, Chitnis T, Weiner HL, Healy BC
Multiple sclerosis and related disorders 2025; (104()):106786 doi:10.1016/j.msard.2025.106786.
PMID: 41101250 - 8
Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach.
Sainz de la Maza S, Gómez-Ballesteros R, Borges M, et al.
Multiple sclerosis journal - experimental, translational and clinical 2023; (9(2)):20552173231169475 doi:10.1177/20552173231169475.
PMID: 37187856 - 9
Cognitive progression independent of relapse in multiple sclerosis.
Fuchs TA, Schoonheim MM, Zivadinov R, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2024; (30(11-12)):1468-1478 doi:10.1177/13524585241256540.
PMID: 39193699 - 10
Determination of disability progression in moderately and highly disabled ambulatory patients with relapsing-remitting multiple sclerosis using the EDSS-Plus: A prospective study in Argentina.
Alonso R, Eizaguirre MB, Casas M, et al.
Multiple sclerosis and related disorders 2025; (99()):106453 doi:10.1016/j.msard.2025.106453.
PMID: 40300408 - 11
Uncovering disability progression in people with multiple sclerosis: a practical guide.
Van Wijmeersch B, Oreja-Guevara C, Magyari M, et al.
Journal of neurology 2026; (273(11)).
PMID: 42975661 - 12
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A, Schaedelin S, Barakovic M, et al.
JAMA neurology 2022; (79(7)):682-692 doi:10.1001/jamaneurol.2022.1025.
PMID: 35575778 - 13
Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.
Lauerer M, McGinnis J, Bussas M, et al.
Journal of neurology, neurosurgery, and psychiatry 2023; (95(1)):37-43 doi:10.1136/jnnp-2023-331799.
PMID: 37495267 - 14
Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis.
Opfer R, Spies L, Krüger J, et al.
Journal of neurology 2025; (272(11)):715 doi:10.1007/s00415-025-13343-2.
PMID: 41117837 - 15
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Kalincik T, Diouf I, Sharmin S, et al.
Neurology 2021; (96(5)):e783-e797 doi:10.1212/WNL.0000000000011242.
PMID: 33372028 - 16
Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis.
Iaffaldano P, Lucisano G, Guerra T, et al.
Annals of clinical and translational neurology 2025; (12(10)):2012-2019 doi:10.1002/acn3.70131.
PMID: 40619726 - 17
Early use of high-efficacy disease-modifying therapies reduces the risk of progression independent of relapse and MRI activity in patients with relapsing-remitting multiple sclerosis.
Guarnaschelli MF, Marrodan M, Sosa BE, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2026; (32(7)):737-746 doi:10.1177/13524585261442036.
PMID: 42057337 - 18
Comparative effects of pilates-based interventions on functional mobility, balance, fatigue, and quality of life in people with multiple sclerosis: a systematic review and network meta-analysis.
Nabil Y, Mansour A, Mohamed AA, et al.
BMC sports science, medicine & rehabilitation 2026; (18(1)).
PMID: 42400084 - 19
Effects of high-speed power training on muscle strength and power in patients with multiple sclerosis.
Medina-Perez C, de Souza-Teixeira F, Fernandez-Gonzalo R, et al.
Journal of rehabilitation research and development 2016; (53(3)):359-68 doi:10.1682/JRRD.2014.08.0186.
PMID: 27270470 - 20
Reconsidering Rehabilitation and Lifestyle Approaches to Improve Quality of Life in People with Multiple Sclerosis: A Scoping Review.
Basalic EB, Roman NA, Minzatanu D, et al.
Medicina (Kaunas, Lithuania) 2026; (62(1)) doi:10.3390/medicina62010215.
PMID: 41597501
This page is for informational purposes only and does not constitute medical advice. A neurologist should evaluate any new or gradually worsening symptoms, including whether they reflect a relapse, pseudo-relapse, or progression.